Avoid recurrent microbial contamination using trending of historical data. El Azab Walid Technical Service Manager STERIS

Similar documents
Case study Microbiological excursion during a phase I PQ of a WFI system. Walid El Azab Technical Service Manager STERIS Life Science

Is it true, Annex 1 revision will have no impact on resources or cost? Walid El Azab Technical Service Manager STERIS

Residue removal in Cleanroom Environments

Disinfection Qualification Testing

Current Industry Trends -Including Cleaning and Disinfection trends, Disinfectant Validation Trends, and Current Warning Letter Activity.

How to Handle Excursions in Environmental Monitoring (EM) and Personnel Monitoring (PM) in an Aseptic Processing Plant

Microbiological Cleaning Method Validation

DISINFECTION QUALIFI CATION TESTING CONSIDERATIONS FOR THE ASEPTIC AND CLEANROOM MANUFACTURING ENVIRONMENT

The Life Cycle Approach to Cleaning Validation

Preparing Your Aseptic Processing Facility for an FDA Inspection. Valerie Welter, Director Quality Bayer HealthCare March 10, 2014

Subpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit.

Managing Your Environmental Isolates

BFS IOA BFS Training 2018 Kunming Qualification and Validation of a BFS-Installation including CIP/SIP

A Case Study for an Improved Approach to Cleanroom Disinfection, Minimizing the Impact and Reducing Downtime

LUNCH AND LEARN. September 11, CE Activity Information & Accreditation

3/5/2013. Agenda. Disinfectant regulations. Case History by Mary Ellen Clark Validation Scientist MedImmune

Bioburden Contamination Control: A Holistic Overview

An Audit Approach to Address Microbial Contamination in Process Equipment

The Parenteral Drug Association

Overview of Regulatory Requirements for API and Formulations

PDA: A Global. Association. Contamination Control: Particles, Bio-contamination, Aseptic manufacturing. PDA Parenteral 2014 Munich Conference

Curriculum Vitae. SENIOR VICE PRESIDENT JAMES P. KULLA Mobile Phone:

PDA: A Global Association

Robert Westney, M.S., RAC, CMQ/OE Director of Quality and Operations Cryologics, Inc. March 7, 2017

Getting it Right Microbial Quality Risk Management

Regulatory Aspects of Cleaning and Cleaning Validation. Larry Greenstein Quality Operations, Quality Unit, Bio-Technology General, Ltd.

A risk based approach to managing environmental excursions

Best Practices For Cleaning Validation in the Aseptic Environment SUMMARY OF OUTLINE

Cleaning and Sanitation

School of Pharmacy & Pharmaceutical Sciences QP Forum Thursday 16th April McGee Pharma International

Overview of Inspection Issues with Legacy Products

Sterilizing and Bioburden Filter Risk Assessment in Vaccine Processes as part of QRM


EU Guidance / Q&A. Greg McGurk, GMP Manager (acting) GMP Conference. 7 February 2017 Dublin

Inspections, Compliance, Enforcement, and Criminal Investigations

Hot Topics in Drug Product Process Validation: A Reviewer s Perspective

Contents. Contents (13) 1 Production (23)

Complaints Investigations Root Cause Analysis

Guidance for Industry

FDA s Guidance for Industry

Compounding Pharmacies and Water

Webinar Expert Module 3: GMP Inspections Dupont

Inspections, Compliance, Enforcement, and Criminal Investigations

Disinfectant Qualification A Multifaceted Study

Cleaning Procedures. These guidelines are intended for Bulk Pharmaceutical Chemicals but almost every word applies to Drug Products

Supplementary Training Modules on Good Manufacturing Practice. Validation. WHO Technical Report Series, No. 937, Annex 4.

Formulated Chemistries for Critical Environments

At Your ServIce. Microbiology Services. The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.

USP <1116> and Contamination


Systems-Based Inspections for Cleaning Validation

Microbiology Research Associates

This compilation of the complex

PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.

Biological contamination events in isolators: What lessons can be learned?

GMP Regulations for Pharmaceutical Industry

Managing Your Environmental Isolates

Testo Expert Knowledge. The GxP Dictionary 1st edition. Definitions relating to GxP and Quality Assurance

Emcure Pharmaceuticals Limited 3/3/16

SITE MASTER FILE For MHRA

Today s Topics. General Quality Control Best Practices. Practices Antimicrobial Effectiveness Testing(AET) Best Practices Environmental Isolates

Overview of Inspection Issues with Legacy Products. Barbara Breithaupt Consumer Safety Officer

GMP GUIDELINES. GMP Guides from Industry Organisations. FDA cgmp WHO GMP. cgmp Guide Drugs 21 CFR 210 GAMP. ISPE Technical Guides

Best Practice in Environmental Monitoring

Technical Report No. 70 Fundamentals of Cleaning and Disinfection Programs for Aseptic Manufacturing Facilities

Microbiological Consideration for Non-Sterile Pharmaceutical

Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer

Journal of Atoms and Molecules

Calibration in the Laboratory

Microbiology Testing: USP requirements for Sterile and Nonsterile Preparations Webinar Q&A

for IND and RDRC Regulated PET Compounding

GMP Manual. Contents. Contents (1) 1 Pharmaceutical Quality System (PQS) 2 Personnel

Compounding Pharmacies and the USP <71> Sterility Tests

On-Site GMP Training GMP COMPLIANCE TECHNICAL

Equipment Design Consideration for Cleaning & Cleaning Validation

Library Guide: Active Pharmaceutical

Outsourcing - managing risks and opportunities over which you now have less control

MICROBIOLOGICAL CULTURE MEDIA

Aseptic Process Validation

Environmental Monitoring of Aseptic Processing Areas - 1

Webinar. The New EU-GMP Annex 1 draft Dupont. GOP-Innovations your Partner for Practical Training and e-learning. 8 June 2018

Industry Case Study: A Microbial Investigation of Contamination by Burkholderia multivorans. Jim Klein and Geert Verdonk Merck & Co., Inc.

Julie Roberts. Audit hot Topics and Regulatory Requirements

T H E P R O P O S A L F O R T H E Y E A R

COMPLIANCE WITH EU ANNEX 15: VALIDATION AND QUALIFICATION

WARNING LETTER AUG 3, 2016

IN THIS SECTION MICROBIOLOGY TESTING EXPERT SOLUTIONS FOR PRODUCT DEVELOPMENT. Bacterial Endotoxin (LAL) Testing

Trinity College Dublin QP Forum 2017 Tuesday 25 th April

Guidance. Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs DRAFT GUIDANCE

Quality by Design in Critical Filtration Operations

SIX ESSENTIAL WORKFLOW STEPS FOR PAPERLESS, AUTOMATED, END-TO-END ENVIRONMENTAL MONITORING

Overview and Introduction Annex 1 Revision

HVAC and Risk Management RACI Meeting 7 th December Agenda. Design. Project Management. Context. Qualification. Construction

TECHNICAL LEAFLET. MEDI-MEDIA-FILL KIT SUPPLY PACKAGE (Code: MR-25/S)

Change Control Overview

Incremental GMPs. Presented by: Karen S. Ginsbury For: IFF October 31, Nov 02, PCI Pharmaceutical Consulting Israel Ltd.

Porton Biopharma Limited 1/17/17

LABORATORY COMPLIANCE

How is Sterilization Validation Performed by the Medical Device Manufacturer?

Recent USP Updates May, 2013

Transcription:

Avoid recurrent microbial contamination using trending of historical data El Azab Walid Technical Service Manager STERIS

Agenda Factors influencing the cleaning and disinfection performance Recurring microbial contamination observed on the field case studies Good practices for microbial contamination control Conclusion

Regulation Requirements: Cross-contamination Control Management for sterile NON EXHAUSTIVE LIST Contamination Sources : I. Biological Cleaning EU GMP: Annex 15 Chapter 3 and 5 EMA Health based US GMP CFR 211.167 ISPE Risk MaPP PDA TR 29 and 49 PICS/S 006 II. Microorganism Endotoxin Chemical Crosscontamination control Product residue Cleaner residue Other residue Disinfection EU Annex 1 US FDA aseptic guidance and CFR 211.113 PICS/S 009 JP Guidance for sterile manufacturing Who TRS961 Annex 6

Regulation Requirements: Cross-contamination Control Management for non sterile NON EXHAUSTIVE LIST Contamination Sources : I. Biological Cleaning EU GMP: Annex 15 Chapter 3 and 5 EMA Health based Eur. Ph. (5.1.4) US GMP CFR 211.167 ISPE Risk MaPP PDA TR 29 USP <1111> & USP <1112> PICS/S 006 II. Microorganism Chemical Crosscontamination control Product residue Cleaner residue Other residue Disinfection Chapter 3 and 5 CFR 211.113 PICS/S 009 WHO TRS961

Factors influencing microbial contamination

Parameters Affecting Cleaning and Disinfection Performance Equipment design Design is one of the key aspect for effective cleaning and disinfection. 100% recovery should always be reached. Equipment design TACT Time, action, concentration and temperature are considered critical process parameter for effective cleaning Numbers Disinfectant is more effective against low number of microorganism than high number Expiry time TACT Type and resistance Sporicidal agent kills spore and vegetative microorganism. However, non oxidizing disinfectant kill vegetative microorganisms and could kill some spore microorganisms Residue ph & Temperature Numbers Water Hard water could reduce efficacy of many disinfectants Chemistry Type and resistance microorganism Chemistry Residue The choice of the chemistry should depend on the residue nature and aspect Residue should not interfere with the disinfectant efficacy. Rinse strategy should be put in place periodically. Water ph & temperature ph could influence the ionic biding of disinfectant, while temperature could affect the log kill over time (Q10). Expiry time Stability of the component ready to use or diluted need to be assessed. It can flexibility based on the shelf life

Agenda Factors influencing the cleaning and disinfection performance Recurring microbial contamination observed on the field case studies Good practices for microbial contamination control Conclusion

Case study #1: Recurrent microbial contamination of non sterile batches Recurrent deviation CAPA : CIP design dead leg removal 2012 2015 Recurrent deviation CAPA : Increase rinsing step using PW for contact product Increase water system sanitization (from every 4 month 80 C for 30 min -> every 2 month 80 C for 30 min) Increase gloves sanitization (IPA) increase the cleaning/disinfection cleanroom frequency (from weekly to daily)

Case study #1: Recurrent microbial contamination of non sterile batches Equipment a. CIP system design: 1. dead leg 2. hoses connection and management b. Water system (PW) maintenance: 1. presence of rouge confirmed 2. recurrent microbial contamination Method f. Room cleaning and disinfection SOP: 1. disinfectant X efficacy vs EM data 2. absence of sporicidal vs EM data c. Water system (PW) sanitization: 1. temperature, time and frequency 2. periodic chemical sanitization d. Process equipment cleaning: 1. water / equipment microbial status 2. cleaner demonstrated not capable to to remove not remove product residueand remove microbial burden Environment Material e. Equipment/Material flows and control : 1. presence of cartons in the rooms 2. equipment flow were not adequate

Case Study #2: Non conform microbial level in final product QC testing Recurrent deviation : Root cause unidentified Specification change Action put in place : Increase the concentration: Double for the disinfectant X NaOCl from 1% to 2% Increase the contact time: From 15 min to 45 min 2015

Case Study #2: Non conform microbial level in final product QC testing Equipment b. Washing machine deisgn : 1. presence of rouge confirmed 2. recurrent microbial contamination a. Equipment design: 1. presence of rouge (high level) 2. high rugosity of the surfaces crevices & interstice Method d. Room cleaning and disinfection SOP: 1. Inadequate understanding of the disinfectant efficacy vs micro identified c. Process equipment cleaning: 1. Cleaner was inefficient the against microorganism found 2. cleaning cycle was inadequate to ensure effective cleaning visual check not achieved 3. Disinfection program for direct contact area with the product was inadequate Environment Material e. Personnel flow was inadequate f. Material status and maintenance was not enough for effective microbial contamination control

Case Study #3: Trend for microbial contamination deviation is increasing every year 45 Number of microbial contamination deviation 40 35 30 25 20 15 10 5 0 2013 2014 2015 2016

Case Study #3: Trend for microbial contamination deviation is increasing every year EM data from 2014-2016 Non conform EM position from 2014-2016 86 43 0 13 14 6 0 12 25 20 10 14 0 4 8 Air Contact plate contact product non contact product floor 2014 2015 2016

Case study #3: Trend for microbial contamination deviation is increasing every year Equipment a. CIP system design: 1. dead leg 2. manual cleaning defective Method Environment Material b. Process equipment cleaning: 1. cleaner not capable to remove product residue 2. Manual cleaning leading to microbial contamination c. Cleaning of the equipment : 1. cleaning and disinfection method was ineffective (Spaghetti chart) 2. miss-used of the detergent vs efficacy 3. Disinfectant were not qualify for their use 4. cleaning simultaneously non contact and contact product using the same procedure d. Microbial specification is the same e. Non respect of the material flow and the number of equipment authorized in the area per validation protocol

Case study #3: Trend for microbial contamination deviation is increasing every year Short term corrective/preventive actions Actions list A C B D Material Man Method Equipment define adequate material flows clean/unclean increase awareness of microbial contamination factors. review the cleaning and disinfection procedure using a hard surface disinfectant and sporicide review the manual cleaning operation and the cleaning steps riboflavin test for automated equipment with spray ball E F Environment Measure

Case study #3: Trend for microbial contamination deviation is increasing every year Long term corrective/preventive actions Actions list A C B D E Material Man Method Equipment Environment reduce the number of detergent and disinfectant. qualify the disinfectant define adequate material flows clean/unclean update the cleaning validation SOP/protocol qualification and re-training review the cleaning and disinfection procedure based on the disinfectant qualification result knowledge transfer task force review the manual cleaning operation riboflavin test and technical upgrade automatic cleaning increase automation by using mobile skid reduce EM testing from intensive to normal F Measure

Case study #4: Recurrent Microbial Contamination of WFI Systems Position of the non-conformity Results per point of use (2 nd phase I PQ) Samples at start or return loop were conform

Case study #4: Recurrent Microbial Contamination of WFI Systems Source: see the source page

Case study #4: Recurrent Microbial Contamination of WFI Systems Source: see the source page

Case study #4: Recurrent Microbial Contamination of WFI Systems Short and long term corrective/preventive actions Actions list A C B D Material Man Method Equipment purchase more material and develop visual lean tools for material management update the SOP/protocol qualification and re-training design sampling instruction methods and check list knowledge transfer task force qualification and requalification requirement Purchase new valves E F Environment Measure

Case study #4: Recurrent Microbial Contamination of WFI Systems

Case Study #5: Non conform microbial level of tank vessel after cleaning hold time testing Description: Cleaning Revalidation: cleaning PW and rinse PW Recurrent contamination by gram - microorganism : P. aeruginosa and P. picketti Several final product with microbial results under USP <1111> specifications and the P. aeruginosa and R. picketti never identified Remedial action Root cause not found: Sanitization of the water system Water results were always conform Microbial analysis of the equipment after each cleaning Remove the clean hold time Identification of each CFU even under specification because consider as objectionable microorganism! After cleaning a 3 log reduction were achieved Cross functional investigation team / Fish bone and microbial screening risk assessment: Root cause: Equipment intra-design inducing water to stagnate Disinfection process was absent vs the equipment design Disassemble the equipment at the end of the week but not during routine testing Actions put in place but removed: Implement a disinfectant peroxide hydrogen impact on the product coloration

Case Study #6: The disinfectant is not working Description: Grade D and grade C: after application of the phenolic disinfectant the microbial testing is higher than prior application In vitro coupon testing were conform to the specifications with 5 minutes contact time micro identified: Staphylococcus epidermidis, Staphylococcus aureus and other human microorganism. Remedial action Root cause not found: Replace the current disinfectant with another phenolic disinfectant Review the procedure and increase the contact time

Case Study #6: The disinfectant is not working

Agenda Factors influencing the cleaning and disinfection performance Recurring microbial contamination observed on the field case studies Good practices for microbial contamination control Conclusion

Approach for Cleaning and Disinfection Process and non- Process Equipment A Soils and microbial Residue type and level A INDUSTRY PRACTICE Microbial residue: Is the cleaner agent used efficient B Surface And Equipment Design B Material substrate, area classification, design C C Cleaning and disinfection program based on risk based assessment PDA TR13: it is recommended to periodically review challenge testing of the selected sanitizers, disinfectants and sporicide if representative new isolate are routinely recovered in the EM program Source: Image from McDonnell, Antisepsis, Disinfection, and Sterilization: Types, Action, and Resistance 2007, ASM Press

Cleaning and disinfection strategy must be based on the sampling risk level Step 1: Risk Factor determination EXAMPLE Step 2: Risk Factor determination Duration Proximity # People Risk Class Step 3: Design the cleaning and disinfection SOP

Microbial contamination reflect inadequate motion work Assess (Risk-based) and control factor(s) that influence microbial contamination during your manufacturing process Develop robust process, cleaning and disinfection, preventive maintenance program Trend and control your data for preventive action and avoid deviation If a deviation the solution is on the shopfloor and the trending analysis!

Agenda Factors influencing the cleaning and disinfection performance Recurring microbial contamination observed on the field case studies Good practices for microbial contamination control Conclusion

Early collaboration between vendors and end-user will change the trend! 180 2012: #5797 2013: #5050 Center name: Drugs Actual Total # of 483's issued: 2014: #4943 2015: #4751 2016: #4528 21 CFR 211.113 Control of microbiological contamination: (a) 'Procedures designed to prevent objectionable microorganisms in drug products not required to be sterile are not [established] [written] [followed]. Specifically, (b) 'Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include [adequate] validation of the sterilization process. Specifically, 160 140 120 100 80 60 40 20 0 2012 2013 2014 2015 2016 21 CFR 211.113 (a) 21 CFR 211.113 (b) 21 CFR 211.67 (a) 21 CFR 211.67 (b) 21 CFR 211.63 Source: http://www.fda.gov/iceci/inspections/ucm250720.htm 21 CFR 211.67Equipment cleaning and maintenance: (a) 'Equipment and utensils are not [cleaned] [maintained] [sanitized] at appropriate intervals to prevent [malfunctions] [contamination] that would alter the safety, identity, strength, quality or purity of the drug product. Specifically, (b) Written procedures are not [established] [followed] for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product. Specifically, and 'Written procedures for cleaning and maintenance fail to include [assignment of responsibility] [maintenance and cleaning schedules] [description in sufficient detail of methods, equipment and materials used] [description in sufficient detail of the methods of disassembling and reassembling equipment as necessary to assure proper cleaning and maintenance] [instructions for removal or obliteration of previous batch identification] [instructions for protection of clean equipment from contamination prior to use] [parameters relevant to the operation]. Specifically, 21 CFR 211.63 Equipment design, size, and location: Equipment used in the manufacture, processing, packing or holding of drug products is not [of appropriate design] [of adequate size] [suitably located] to facilitate operations for its [intended use] [cleaning and maintenance]. Specifically,

Thank You For your listening El Azab Walid Technical Service Manager STERIS Walid_elazab@steris.com +32479790273

References Parenteral Drug Associations (2014) PDA Technical Report No. 67 : Exclusion of Objectionable Microorganism from Nonsterile Pharmaceuticals, Medical devices and cosmetics. Sutton S..(2012). What is an "Objectionable Organism"?, 2012, American Pharmaceutical Review 15(6):36-48. Sutton, S and L Jimenez. (2012). A Review of Reported Recalls Involving Microbiological Control 2004-2011 with Emphasis on FDA Considerations of Objectionable Organisms, American Pharmaceutical Review 15(1):42-57 Tim Sandle, Assessment of the suitability of the R3A agar for the subculture of microorganisms isolated from pharmaceutical water systems. (2014). European Journal of Parenteral & Pharmaceutical Sciences 2014;19(3):85-93 Tim Sandle. (2011). A Review of Cleanroom Microflora: Types, Trends, and Patterns. PDA J Pharm Sci and Tech 2011, 65 392-403 Lopolito, P. and Rivera, E. (2013) An Audit Approach to Address Microbial Contamination in Process Equipment, Volume 1, DHI/PDA, Chapter 15, El Azab W. (2016), Investigation of Microbiological Contamination in Water Systems: A Case Study, Contamination Control in Healthcare Product Manufacturing, Volume 4, DHI/PDA, Chapter 7 Sandle T., Understanding cleanroom flora, The Official Journal of The Institute of Science & Technology Journal, (2013) Sandle T., Peer Reviewed: Cleanroom Contamination, IVT network (people-cleanrooms-understanding-and-monitoring-personnelfactor), (2014). Madsen R., Moldenhauer J., Contamination Control in HealthCare Product Manufacturing, PDA and DHI, Vol. 3, 2013, p. 323-355. Lucia Stecchini M., Del Torre M., Sarais I., Saro O., Messina M., Maltini E., Influence of Structural Properties and Kinetic Constraints on Bacillus cereus Growth, Applied and Environmental Microbiology, 64 (3), (1997). Whyte W., and Eaton T., Microbiological contamination models for use in risk assessment during pharmaceutical production. European Journal of Parenteral and Pharmaceutical Sciences, 9 (1), pp. 11-15 (2004). Whyte W., and Eaton T., Microbial risk assessment in pharmaceutical cleanrooms. European Journal of Parenteral and Pharmaceutical Sciences, 9 (1), 16-23, (2004). Polarine J., Bartnett C., Smith T., Klein D., Karanja P., Peer Reviewed: Fungicidal Activity of Globally Acceptable Quaternary Ammonium Disinfectants, Journal of Validation Technology, 2013 Note: This is not a complete listing, just a guidance to literature the speaker has found to be interesting/beneficial.